ADMA Biologics
ADMA
13.17
-0.17
-1.27%
ADMA Biologics
US · ADMA
#2705 by market cap
Listed 1970
13.17
-0.17
-1.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Cantor Fitzgerald Downgrades ADMA Biologics(ADMA.US) to Hold Rating, Maintains Target Price $30Market Newswire · 2026/3/26
-
Company notice
ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.SEC · 2026/3/11
-
Rating change
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/2/26
-
Company notice
ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.SEC · 2026/4/4
-
Rating change
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21Market Newswire · 2026/4/21
-
Rating change
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $17Market Newswire · 2026/7/15
-
Company notice
ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.SEC · 2026/2/24
-
Rating change
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $24Market Newswire · 2026/4/14
-
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $19Market Newswire · 2026/11/5
-
Company notice
4: ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.SEC · 2026/7/29
-
Rating change
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $20Market Newswire · 2026/5/7
-
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/8/6
-
Rating change
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Cuts Target Price to $12Market Newswire · 2026/8/6
-
Company notice
ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Director Guiheen Lawrence P.SEC · 2026/3/18
-
ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M EstimateBenzinga · 2026/11/5
-
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Raises Target Price to $13Market Newswire · 2026/11/5
-
Rating change
Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21Market Newswire · 2026/6/10
-
Rating change
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/5/5
-
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/11/5
-
Rating change
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2025/11/6
-
Rating change
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35Market Newswire · 2025/5/9
-
Rating change
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32Market Newswire · 2025/8/18
-
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M EstimateBenzinga · 2026/8/6
-
Rating change
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32Market Newswire · 2025/5/9
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ADMA Biologics discussion 0 comments